FluoGuide is a clinical-stage biotech company, elevating precision surgery with FG001, illuminating cancer cells during surgery to enhance outcomes for patients
New - New exchange: Nasdaq First North
FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.
FluoGuide develops drugs for maximizing surgical outcomes by making cancer fluorescent.
Successful application of FluoGuide’s products will lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals.
FluoGuide’s pipeline consists of product candidates that can potentially make most solid cancers fluorescent. We advance our pipeline at a rapid pace for the benefit of patients with cancer, society, and our shareholders. FluoGuide’s lead-product, FG001, is in phase IIa clinical development targeting patients undergoing surgical removal of high-grade glioma. FluoGuide is also developing FG001 in lung cancer and Head & Neck cancer.
14 November 2023
Redeye interview on topline data from ph IIb in aggressive brain cancer
10 November 2023
Interview with Dansk Aktionærforeningen (in Danish)
